LUNDBECK LLC for LUNDBECK LLC
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
S. 525, HR 1298 - Drug Reimportation and impact in inlicensed and out-licensed products, impact on smaller pharmaceutical companies HR 1427, HR 1548, S. 726 - Biosimilar prescription drugs, data exclusivity
Foreign entity interest: H. Lundbeck, identified on LD-1, researches, develops and commercializes medicines that could be imported under an importation program, and global safety of drug supply is a critical issue.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL J EGING | — |
Health Issues HCR
Health care reform, HR 3200, Access to and coverage of Specialty Pharmaceuticals, Removal of patient life-time caps, and specialty tiering of copayments Senate Finance Committee Health Reform Chairman's Mark S. 301 - Physicians payments transparency, preemption of State law
Foreign entity interest: H. Lundbeck, identified on LD-1, researches, develops and commercializes medicines that are utilized by patients in the United States and will be affected by health care reform.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL J EGING | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.